Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Plasma cell 3Genitourinary 3CNS 3Lymphoid 2Gynecologic 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Other 1NET 1Endocrine 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 60Neoplasms 7Gastro-enteropancreatic neuroendocrine tumor 7Carcinoid Tumor 6Breast Neoplasms 6Pheochromocytoma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Adenoma, Islet Cell 5Urinary Bladder Neoplasms 4Thyroid Neoplasms 4Paraganglioma 4Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Neuroendocrine 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Melanoma 3Carcinoma, Medullary 3Adrenocortical Carcinoma 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Testicular Neoplasms 2Sarcoma 2Neuroectodermal Tumors, Primitive 2Lymphoma 2Liver Neoplasms 2

Interventions

Ga(III)-DOTATOC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Disease × NET × Clear all
NCT02359500 2017-05-03

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Icahn School of Medicine at Mount Sinai

Phase 1 Terminated
71 enrolled
EndocrineNET

Carcinoid Tumor, Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡